Manju Subramanian, MD
Ophthalmology · Taunton, MANPI 1144216821
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,813 of the $16,289 with a category attached, or 84.8%. Regeneron accounts for 92.5% of it on its own, with 8 other manufacturers making up the rest. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $542.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$15K
- Novartis$315
- Alcon$300
- Genentech USA, Inc.$177
- Genentech, Inc.$148
- AbbVie$128
- plus $152 from 3 others
Across 3 payments — averaging $767.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
What the payments were for
- Consulting fees$13,81385%
- Travel & lodging$1,0637%
- Food & beverage$1,4139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 16 | $15,068 |
| Novartis | 3 | $315 |
| Alcon | 2 | $300 |
| Genentech USA, Inc. | 3 | $177 |
| Genentech, Inc. | 1 | $148 |
| AbbVie | 2 | $128 |
| Eyepoint US, Inc. | 1 | $107 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,289 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 80 | $2,098 |
| Latanoprost | 86 | $1,234 |
| Prednisolone Acetate | 26 | $985 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 51 | $915 |
| Dorzolamide Hcl | 20 | $490 |
| Timolol Maleate | 19 | $293 |
| Ketorolac Tromethamine | 21 | $164 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Taunton
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
- Mina FarahaniBoston$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.